Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2/3 1

Status

Completed 3Terminated 2Unknown 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2

Conditions

Urinary Bladder Neoplasms 2Neoplasms 2Carcinoma, Transitional Cell 2Carcinoma in Situ 2Virus Diseases 1Urologic Neoplasms 1Urologic Diseases 1Urogenital Neoplasms 1Urinary Bladder Diseases 1Non-Muscle Invasive Bladder Neoplasms 1Neoplasms by Site 1Adenoviridae Infections 1

Interventions

Gemcitabine 25Cisplatin 19pembrolizumab 11avelumab 10Nivolumab 7Mitomycin 6Carboplatin 6apaziquone 5Paclitaxel 5Vinblastine 4Methotrexate 4Doxorubicin 4Docetaxel 4BCG Vaccine 4vofatamab 3durvalumab 3atezolizumab 3Sunitinib 3Standard of Care 3Sorafenib 3Radiotherapy, Intensity-Modulated 3Radiotherapy 3Radiation 3Magnetic Resonance Spectroscopy 3Lapatinib 3Cystectomy 3B701 protein, Human herpesvirus 6 3valrubicin 2rucaparib 2enfortumab vedotin 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Terminated × Urinary Bladder Neoplasms × valrubicin × Clear all
NCT01438112 2021-04-14

BOND

CG Oncology, Inc.

Phase 2/3 Terminated
22 enrolled
Genitourinary

Adenoviridae Infections, Urinary Bladder Neoplasms, Carcinoma in Situ, Carcinoma, Transitional Cell, Neoplasms, Virus Diseases

NCT01310803 2017-10-05

Multi-center Study to Evaluate the Efficacy and Safety of Maintenance Therapy With Valrubicin Versus no Maintenance, in Subjects Treated With Valrubicin Induction for Carcinoma in Situ (CIS) of the Bladder

Endo Pharmaceuticals

Phase 3 Terminated
1 enrolled 5 charts
Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Diseases, Urinary Bladder Neoplasms, Carcinoma in Situ, Carcinoma, Transitional Cell, Neoplasms, Neoplasms by Site, Urogenital Neoplasms, Urologic Diseases, Urologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡